Hypomethylation and the Resultant Overexpressed PARM1: a Biomarker for Poor Prognosis of Diffuse Large B-cell Lymphoma

被引:0
|
作者
Cao, Baoping [1 ]
Guo, Xiaochuan [1 ]
Wang, Bin [1 ]
Wang, Weixia [1 ]
Han, Dong [1 ]
Zhang, Weijing [1 ]
Zhong, Kaili [1 ]
机构
[1] Capital Med Univ, Beijing Shijitan Hosp, Dept Lymphoma, Beijing 100038, Peoples R China
关键词
WEB SERVER; CANCER; AUTOPHAGY; INHIBITION; RESISTANCE; PROLIFERATION; MUCINS;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Prostate androgen-regulated mucin-like protein (PARM1) is known to promote cell survival via protecting the cell surface, thus being involved in cancer development. The Gene Expression Profiling Interactive Analysis (GEPIA), MEXPRESS database, LinkedOmics database, GeneMANIA database, and the Tumor Immune Estimation Resource (TIMER) database were accessed to explore the epigenetic regulation, prognostic value, biological functions and mechanisms of PARM1 in diffuse large B-cell lymphoma (DLBCL). Hypomethylation and resultant overexpression of PARM1 was found in DLBCL. The high-level expression of PARM1 was related to the poor outcome of DLBCL patients. PARM1 participated in DNA repair, cell cycle, and cellular response to stress. PARM1 was also associated with autophagy, apoptosis, Ras pathway, and MAPK cascade. Significant kinase targets of PARM1 included ATM, CDK1, and CDK2. Significant transcription factor targets of PARM1 involved ELK1, MYC and so on. Significant miRNA targets of PARM1 included miR21, miR202, miR323, and miR345. Further analysis suggested that the PARM1 regulated autophagy through the PI3K-Akt signaling. PARM1 was found to be correlated with immune cell infiltration, which indicated the important roles of PARM1 in microenvironment of DLBCL. Our study lays a foundation for further research on the impact of PARM1 in DLBCL tumorigenesis and precision therapy.
引用
收藏
页码:27 / 40
页数:14
相关论文
共 50 条
  • [21] Estrogen receptor β1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker
    Hasni, Muhammad Sharif
    Berglund, Mattias
    Yakimchuk, Konstantin
    Guan, Jiyu
    Linderoth, Johan
    Amini, Rose Marie
    Enblad, Gunilla
    Okret, Sam
    LEUKEMIA & LYMPHOMA, 2017, 58 (02) : 418 - 427
  • [22] Increased MALAT1 expression predicts poor prognosis in primary gastrointestinal diffuse large B-cell lymphoma
    Qian, Zhengzi
    Chen, Leiyuan
    Wang, Xinyuan
    Kan, Yutian
    Wang, Yafei
    Yu, Yong
    Wang, Xiaofang
    Zhao, Zhigang
    Yang, Hongliang
    Ge, Peng
    Ding, Tingting
    Zhai, Qiongli
    Zhao, Haifeng
    CLINICAL AND EXPERIMENTAL MEDICINE, 2022, 22 (02) : 183 - 191
  • [23] TNF-α Receptor 1 Expression Predicts Poor Prognosis of Diffuse Large B-cell Lymphoma, Not Otherwise Specified
    Nakayama, Shoko
    Yokote, Taiji
    Tsuji, Motomu
    Akioka, Toshikazu
    Miyoshi, Takuji
    Hirata, Yuji
    Hiraoka, Nobuya
    Iwaki, Kazuki
    Takayama, Ayami
    Nishiwaki, Uta
    Masuda, Yuki
    Nishimura, Yasuichiro
    Hanafusa, Toshiaki
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2014, 38 (08) : 1138 - 1146
  • [24] E2f-1: A marker of treatment failure and poor prognosis in diffuse large B-cell lymphoma
    Moller, MB
    Kania, PW
    Ino, Y
    Gerdes, AM
    Nielsen, O
    Louis, DN
    Skjodt, K
    Pedersen, NT
    Borregaard, N
    BLOOD, 1999, 94 (10) : 510A - 510A
  • [25] Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients
    Manfroi, B.
    Moreaux, J.
    Righini, C.
    Ghiringhelli, F.
    Sturm, N.
    Huard, B.
    BLOOD CANCER JOURNAL, 2018, 8
  • [26] Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma
    You, Hua
    Xu-Monette, Zijun Y.
    Wei, Li
    Nunns, Harry
    Nagy, Mate L.
    Bhagat, Govind
    Fang, Xiaosheng
    Zhu, Feng
    Visco, Carlo
    Tzankov, Alexandar
    Dybkaer, Karen
    Chiu, April
    Tam, Wayne
    Zu, Youli
    Hsi, Eric D.
    Hagemeister, Fredrick B.
    Huh, Jooryung
    Ponzoni, Maurilio
    Ferreri, Andres J. M.
    Moller, Michael B.
    Parsons, Benjamin M.
    Van Krieken, J. Han
    Piris, Miguel A.
    Winter, Jane N.
    Li, Yong
    Au, Qingyan
    Xu, Bing
    Albitar, Maher
    Young, Ken H.
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [27] High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma
    Carreras, Joaquim
    Kikuti, Yara Yukie
    Hiraiwa, Shinichiro
    Miyaoka, Masashi
    Tomita, Sakura
    Ikoma, Haruka
    Ito, Atsushi
    Kondo, Yusuke
    Itoh, Johbu
    Roncador, Giovanna
    Martinez, Antonio
    Colomo, Lluis
    Hamoudi, Rifat
    Ando, Kiyoshi
    Nakamura, Naoya
    CANCER SCIENCE, 2022, 113 (01) : 334 - 348
  • [28] Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients
    B. Manfroi
    J. Moreaux
    C. Righini
    F. Ghiringhelli
    N. Sturm
    B. Huard
    Blood Cancer Journal, 8
  • [29] Strong HDAC6 Expression Is Associated with Poor Prognosis of Diffuse Large B-Cell Lymphoma
    Zhou, X.
    Cai, Y.
    Cui, W.
    Wang, W.
    Liu, Z.
    Wei, P.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (06): : 863 - 864
  • [30] Anaplastic Lymphoma Kinase-Positive Diffuse Large B-Cell Lymphoma: A Rare Clinicopathologic Entity With Poor Prognosis
    Laurent, Camille
    Do, Catherine
    Gascoyne, Randy D.
    Lamant, Laurence
    Ysebaert, Loic
    Laurent, Guy
    Delsol, Georges
    Brousset, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : 4211 - 4216